Laurie Goodrich
Concepts (374)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Horse Diseases | 42 | 2025 | 63 | 11.220 |
Why?
| | Horses | 86 | 2025 | 204 | 9.280 |
Why?
| | Cartilage, Articular | 19 | 2024 | 340 | 3.730 |
Why?
| | Osteoarthritis | 12 | 2024 | 193 | 3.600 |
Why?
| | Mesenchymal Stem Cell Transplantation | 9 | 2024 | 59 | 3.550 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 4 | 2024 | 254 | 2.540 |
Why?
| | Chondrocytes | 14 | 2023 | 231 | 2.510 |
Why?
| | Genetic Therapy | 11 | 2024 | 322 | 2.320 |
Why?
| | Lameness, Animal | 14 | 2023 | 23 | 2.300 |
Why?
| | Bone Marrow Cells | 7 | 2019 | 320 | 2.180 |
Why?
| | Stifle | 10 | 2019 | 14 | 1.990 |
Why?
| | Genetic Vectors | 11 | 2023 | 342 | 1.890 |
Why?
| | Arthroscopy | 13 | 2023 | 244 | 1.760 |
Why?
| | Fractures, Bone | 8 | 2023 | 416 | 1.710 |
Why?
| | Dependovirus | 5 | 2022 | 78 | 1.680 |
Why?
| | Orthopedics | 5 | 2023 | 160 | 1.550 |
Why?
| | Animals | 102 | 2025 | 38140 | 1.540 |
Why?
| | Chondrogenesis | 4 | 2025 | 89 | 1.490 |
Why?
| | Forelimb | 8 | 2025 | 39 | 1.350 |
Why?
| | Cartilage Diseases | 4 | 2018 | 45 | 1.180 |
Why?
| | Transduction, Genetic | 8 | 2022 | 136 | 1.150 |
Why?
| | Fracture Healing | 2 | 2019 | 89 | 1.090 |
Why?
| | Musculoskeletal Diseases | 5 | 2022 | 88 | 1.020 |
Why?
| | Osteogenesis | 2 | 2019 | 205 | 1.020 |
Why?
| | Synovial Membrane | 5 | 2024 | 123 | 1.000 |
Why?
| | Ligaments | 4 | 2016 | 78 | 0.990 |
Why?
| | Tendons | 5 | 2025 | 128 | 0.980 |
Why?
| | Arthritis, Infectious | 2 | 2024 | 72 | 0.950 |
Why?
| | Bone Morphogenetic Protein 2 | 4 | 2019 | 75 | 0.940 |
Why?
| | Platelet-Rich Plasma | 3 | 2022 | 37 | 0.940 |
Why?
| | Osteomyelitis | 2 | 2023 | 142 | 0.910 |
Why?
| | Tarsal Bones | 2 | 2023 | 14 | 0.900 |
Why?
| | Insulin-Like Growth Factor I | 5 | 2015 | 320 | 0.860 |
Why?
| | Injections, Intra-Articular | 8 | 2021 | 57 | 0.860 |
Why?
| | Manure | 1 | 2024 | 10 | 0.860 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2020 | 681 | 0.820 |
Why?
| | Metatarsal Bones | 1 | 2023 | 21 | 0.800 |
Why?
| | Fasting | 1 | 2024 | 282 | 0.740 |
Why?
| | Bone Plates | 4 | 2018 | 80 | 0.730 |
Why?
| | Perioperative Care | 1 | 2024 | 223 | 0.710 |
Why?
| | Veterinarians | 1 | 2021 | 12 | 0.700 |
Why?
| | Synovitis | 2 | 2020 | 33 | 0.690 |
Why?
| | Tomography, X-Ray Computed | 8 | 2024 | 2782 | 0.690 |
Why?
| | Elephants | 1 | 2021 | 6 | 0.690 |
Why?
| | Tissue Engineering | 5 | 2020 | 440 | 0.670 |
Why?
| | Wound Healing | 6 | 2018 | 361 | 0.670 |
Why?
| | Bone Regeneration | 1 | 2020 | 27 | 0.640 |
Why?
| | High-Energy Shock Waves | 1 | 2019 | 4 | 0.630 |
Why?
| | Orthopedic Procedures | 3 | 2015 | 233 | 0.620 |
Why?
| | Cell Culture Techniques | 3 | 2020 | 379 | 0.620 |
Why?
| | Synovial Fluid | 5 | 2020 | 67 | 0.600 |
Why?
| | Fibrin | 3 | 2023 | 91 | 0.580 |
Why?
| | Acute Disease | 2 | 2020 | 996 | 0.560 |
Why?
| | Cell Differentiation | 6 | 2025 | 2045 | 0.560 |
Why?
| | Cryopreservation | 1 | 2019 | 110 | 0.540 |
Why?
| | Contrast Media | 8 | 2024 | 486 | 0.520 |
Why?
| | Osteoporotic Fractures | 1 | 2018 | 62 | 0.510 |
Why?
| | Magnetic Resonance Imaging | 8 | 2023 | 3834 | 0.500 |
Why?
| | Lymphokines | 1 | 2017 | 130 | 0.500 |
Why?
| | Recovery of Function | 2 | 2020 | 695 | 0.490 |
Why?
| | Hydrogels | 3 | 2018 | 692 | 0.480 |
Why?
| | Electrosurgery | 1 | 2015 | 42 | 0.440 |
Why?
| | Antibodies, Neutralizing | 2 | 2015 | 344 | 0.440 |
Why?
| | Foot Joints | 1 | 2014 | 3 | 0.430 |
Why?
| | Disease Models, Animal | 9 | 2018 | 4553 | 0.430 |
Why?
| | Cell Proliferation | 3 | 2017 | 2540 | 0.430 |
Why?
| | Biocompatible Materials | 1 | 2018 | 436 | 0.430 |
Why?
| | Ultrasonography | 3 | 2016 | 766 | 0.420 |
Why?
| | Autoantigens | 1 | 2017 | 429 | 0.410 |
Why?
| | Chronic Disease | 1 | 2020 | 1826 | 0.410 |
Why?
| | Leukocytes, Mononuclear | 1 | 2017 | 580 | 0.410 |
Why?
| | Capsid | 1 | 2014 | 94 | 0.410 |
Why?
| | Analgesics | 2 | 2008 | 229 | 0.410 |
Why?
| | Radiography | 9 | 2023 | 838 | 0.400 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 2620 | 0.380 |
Why?
| | Dogs | 3 | 2024 | 437 | 0.370 |
Why?
| | Gene Expression | 3 | 2015 | 1512 | 0.370 |
Why?
| | Proof of Concept Study | 2 | 2025 | 83 | 0.360 |
Why?
| | Arthrodesis | 3 | 2018 | 35 | 0.350 |
Why?
| | Tenosynovitis | 1 | 2011 | 11 | 0.350 |
Why?
| | Sports | 1 | 2014 | 213 | 0.340 |
Why?
| | Joint Diseases | 2 | 2016 | 62 | 0.340 |
Why?
| | Extremities | 2 | 2023 | 141 | 0.340 |
Why?
| | Cartilage | 4 | 2021 | 195 | 0.330 |
Why?
| | Anti-Bacterial Agents | 6 | 2023 | 1901 | 0.330 |
Why?
| | Treatment Outcome | 16 | 2020 | 11459 | 0.320 |
Why?
| | Cells, Cultured | 7 | 2025 | 4172 | 0.320 |
Why?
| | Synoviocytes | 2 | 2021 | 18 | 0.320 |
Why?
| | Postoperative Complications | 6 | 2018 | 2894 | 0.320 |
Why?
| | Antibodies, Viral | 1 | 2014 | 684 | 0.310 |
Why?
| | Cadaver | 5 | 2025 | 301 | 0.310 |
Why?
| | Hindlimb | 5 | 2018 | 136 | 0.310 |
Why?
| | Female | 32 | 2024 | 77569 | 0.300 |
Why?
| | Fracture Fixation | 2 | 2011 | 81 | 0.300 |
Why?
| | Surgery, Veterinary | 1 | 2008 | 1 | 0.290 |
Why?
| | Foot Diseases | 3 | 2015 | 19 | 0.290 |
Why?
| | Tissue Scaffolds | 3 | 2017 | 221 | 0.290 |
Why?
| | Hoof and Claw | 4 | 2018 | 9 | 0.290 |
Why?
| | Transplantation, Homologous | 2 | 2020 | 414 | 0.280 |
Why?
| | Models, Animal | 4 | 2023 | 394 | 0.280 |
Why?
| | Random Allocation | 3 | 2018 | 364 | 0.270 |
Why?
| | Cell Survival | 3 | 2021 | 1110 | 0.270 |
Why?
| | Male | 28 | 2024 | 71568 | 0.260 |
Why?
| | Transplantation, Autologous | 2 | 2019 | 290 | 0.250 |
Why?
| | Retrospective Studies | 13 | 2020 | 16755 | 0.240 |
Why?
| | Animals, Zoo | 1 | 2005 | 15 | 0.230 |
Why?
| | Fracture Fixation, Internal | 3 | 2023 | 206 | 0.230 |
Why?
| | Ursidae | 1 | 2005 | 7 | 0.230 |
Why?
| | Inflammation | 4 | 2022 | 2893 | 0.230 |
Why?
| | Steroids | 1 | 2006 | 161 | 0.220 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2006 | 342 | 0.220 |
Why?
| | Carpus, Animal | 2 | 2018 | 2 | 0.210 |
Why?
| | Food Deprivation | 1 | 2024 | 27 | 0.210 |
Why?
| | Animal Feed | 1 | 2024 | 53 | 0.210 |
Why?
| | Ascitic Fluid | 2 | 2014 | 15 | 0.210 |
Why?
| | Phosphorylcholine | 1 | 2023 | 19 | 0.200 |
Why?
| | Bursa, Synovial | 2 | 2015 | 3 | 0.200 |
Why?
| | Dog Diseases | 1 | 2024 | 70 | 0.200 |
Why?
| | Vitamin D Deficiency | 1 | 2005 | 187 | 0.200 |
Why?
| | X-Ray Microtomography | 2 | 2023 | 105 | 0.190 |
Why?
| | Regenerative Medicine | 2 | 2020 | 52 | 0.190 |
Why?
| | Fluoroscopy | 1 | 2023 | 168 | 0.190 |
Why?
| | Serogroup | 1 | 2022 | 44 | 0.190 |
Why?
| | Serotyping | 2 | 2014 | 32 | 0.190 |
Why?
| | Cell- and Tissue-Based Therapy | 2 | 2024 | 83 | 0.190 |
Why?
| | Anesthesia, Epidural | 1 | 2002 | 12 | 0.180 |
Why?
| | Animal Migration | 1 | 2022 | 39 | 0.180 |
Why?
| | T-Lymphocytes | 2 | 2024 | 2041 | 0.180 |
Why?
| | Osteonectin | 2 | 2019 | 4 | 0.180 |
Why?
| | Birds | 1 | 2022 | 91 | 0.180 |
Why?
| | Osteocalcin | 2 | 2019 | 38 | 0.180 |
Why?
| | Amikacin | 2 | 2020 | 28 | 0.180 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 2 | 2019 | 45 | 0.180 |
Why?
| | Proteoglycans | 3 | 2014 | 109 | 0.180 |
Why?
| | Adenoviridae | 4 | 2007 | 203 | 0.170 |
Why?
| | Alkaline Phosphatase | 2 | 2019 | 144 | 0.170 |
Why?
| | Nervous System Diseases | 1 | 2024 | 280 | 0.170 |
Why?
| | Morphine | 1 | 2002 | 167 | 0.170 |
Why?
| | Pilot Projects | 2 | 2023 | 1851 | 0.170 |
Why?
| | Imidazoles | 1 | 2002 | 255 | 0.160 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 2021 | 86 | 0.160 |
Why?
| | One Health | 1 | 2020 | 10 | 0.160 |
Why?
| | Postoperative Period | 2 | 2019 | 353 | 0.160 |
Why?
| | Rabbits | 2 | 2018 | 656 | 0.160 |
Why?
| | Tenocytes | 1 | 2020 | 5 | 0.160 |
Why?
| | Occlusive Dressings | 1 | 2000 | 6 | 0.160 |
Why?
| | Immunomodulation | 1 | 2021 | 102 | 0.160 |
Why?
| | Collagen Type III | 1 | 2019 | 18 | 0.160 |
Why?
| | Amnion | 1 | 2000 | 28 | 0.160 |
Why?
| | Toll-Like Receptors | 1 | 2021 | 190 | 0.160 |
Why?
| | Adipogenesis | 1 | 2020 | 57 | 0.150 |
Why?
| | Polymers | 1 | 2023 | 500 | 0.150 |
Why?
| | Skin Transplantation | 1 | 2000 | 86 | 0.150 |
Why?
| | Humans | 16 | 2023 | 143817 | 0.150 |
Why?
| | Analgesia | 1 | 2020 | 102 | 0.150 |
Why?
| | Phagocytosis | 1 | 2021 | 297 | 0.150 |
Why?
| | Peptides | 1 | 2025 | 986 | 0.150 |
Why?
| | Toe Joint | 1 | 2018 | 5 | 0.150 |
Why?
| | Laparoscopy | 2 | 2014 | 476 | 0.140 |
Why?
| | California | 1 | 2020 | 464 | 0.140 |
Why?
| | Anterior Cruciate Ligament | 1 | 2019 | 80 | 0.140 |
Why?
| | Stem Cells | 2 | 2020 | 622 | 0.140 |
Why?
| | Bone Marrow | 1 | 2020 | 303 | 0.140 |
Why?
| | Leiomyoma | 1 | 1998 | 59 | 0.140 |
Why?
| | Injections | 2 | 2017 | 194 | 0.140 |
Why?
| | Sheep | 2 | 2020 | 871 | 0.140 |
Why?
| | Culture Media | 1 | 2018 | 160 | 0.140 |
Why?
| | Low-Level Light Therapy | 1 | 2017 | 7 | 0.140 |
Why?
| | Tibia | 2 | 2016 | 189 | 0.130 |
Why?
| | Interleukin-1beta | 1 | 2020 | 396 | 0.130 |
Why?
| | Lasers, Solid-State | 1 | 2017 | 23 | 0.130 |
Why?
| | Extracellular Matrix | 2 | 2018 | 563 | 0.130 |
Why?
| | Ligaments, Articular | 1 | 2017 | 52 | 0.130 |
Why?
| | Parathyroid Hormone | 1 | 2018 | 112 | 0.130 |
Why?
| | Collateral Ligaments | 1 | 1997 | 17 | 0.130 |
Why?
| | Blood Platelets | 2 | 2023 | 396 | 0.130 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 856 | 0.130 |
Why?
| | Tissue Culture Techniques | 2 | 2014 | 82 | 0.130 |
Why?
| | Calcaneus | 1 | 1997 | 31 | 0.130 |
Why?
| | Animal Welfare | 1 | 2017 | 18 | 0.130 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2019 | 559 | 0.130 |
Why?
| | Staphylococcus aureus | 1 | 2021 | 449 | 0.130 |
Why?
| | Arthrography | 2 | 2016 | 18 | 0.130 |
Why?
| | Stem Cell Transplantation | 1 | 2018 | 190 | 0.120 |
Why?
| | Follow-Up Studies | 4 | 2016 | 5317 | 0.120 |
Why?
| | Connective Tissue | 1 | 2016 | 39 | 0.120 |
Why?
| | Knee Injuries | 1 | 2017 | 102 | 0.120 |
Why?
| | Range of Motion, Articular | 2 | 2018 | 415 | 0.120 |
Why?
| | Anterior Cruciate Ligament Injuries | 1 | 2019 | 172 | 0.120 |
Why?
| | Gene Ontology | 1 | 2015 | 53 | 0.120 |
Why?
| | Dexamethasone | 2 | 2025 | 373 | 0.120 |
Why?
| | Carpal Joints | 1 | 2015 | 2 | 0.110 |
Why?
| | Biopsy, Needle | 1 | 2016 | 184 | 0.110 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2015 | 77 | 0.110 |
Why?
| | Biological Products | 1 | 2019 | 252 | 0.110 |
Why?
| | Colectomy | 1 | 1996 | 107 | 0.110 |
Why?
| | Glycosaminoglycans | 3 | 2020 | 79 | 0.110 |
Why?
| | Transgenes | 1 | 2015 | 188 | 0.110 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 1996 | 124 | 0.110 |
Why?
| | Neutralization Tests | 1 | 2014 | 80 | 0.110 |
Why?
| | Accelerometry | 1 | 2015 | 119 | 0.110 |
Why?
| | Time Factors | 3 | 2019 | 7068 | 0.100 |
Why?
| | Statistics, Nonparametric | 1 | 2015 | 431 | 0.100 |
Why?
| | Research Design | 2 | 2019 | 1121 | 0.100 |
Why?
| | Ovariectomy | 1 | 2014 | 161 | 0.100 |
Why?
| | Gene Expression Profiling | 2 | 2024 | 1817 | 0.100 |
Why?
| | Cytokines | 2 | 2021 | 2093 | 0.100 |
Why?
| | Colonic Neoplasms | 1 | 1996 | 262 | 0.100 |
Why?
| | Granular Cell Tumor | 1 | 1993 | 8 | 0.100 |
Why?
| | Immunohistochemistry | 2 | 2016 | 1733 | 0.100 |
Why?
| | Sequence Analysis, RNA | 1 | 2015 | 445 | 0.100 |
Why?
| | Bone Morphogenetic Protein 7 | 2 | 2010 | 12 | 0.100 |
Why?
| | Cryptorchidism | 1 | 2012 | 17 | 0.100 |
Why?
| | Cattle | 2 | 2014 | 1004 | 0.100 |
Why?
| | Lymphocyte Activation | 1 | 2017 | 1143 | 0.090 |
Why?
| | Cations | 2 | 2024 | 83 | 0.090 |
Why?
| | Testis | 1 | 2012 | 166 | 0.090 |
Why?
| | Orthopedic Fixation Devices | 1 | 2011 | 8 | 0.090 |
Why?
| | Postoperative Care | 1 | 2014 | 278 | 0.090 |
Why?
| | Wounds and Injuries | 1 | 2000 | 949 | 0.090 |
Why?
| | Foot | 1 | 2012 | 102 | 0.090 |
Why?
| | Running | 1 | 2014 | 232 | 0.090 |
Why?
| | Skin Neoplasms | 1 | 1998 | 860 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2925 | 0.080 |
Why?
| | Colorado | 1 | 2020 | 4578 | 0.080 |
Why?
| | Osteoblasts | 1 | 2010 | 144 | 0.080 |
Why?
| | RNA, Messenger | 3 | 2007 | 2847 | 0.080 |
Why?
| | Catheterization | 1 | 2010 | 182 | 0.070 |
Why?
| | Arthroscopes | 1 | 2008 | 1 | 0.070 |
Why?
| | Education, Veterinary | 1 | 2008 | 4 | 0.070 |
Why?
| | Cysts | 1 | 2010 | 111 | 0.070 |
Why?
| | Bone Cysts | 1 | 2008 | 11 | 0.070 |
Why?
| | In Situ Hybridization | 2 | 2006 | 320 | 0.070 |
Why?
| | Biomarkers | 1 | 2019 | 4248 | 0.070 |
Why?
| | Femur | 3 | 2016 | 271 | 0.070 |
Why?
| | Intraoperative Complications | 1 | 2008 | 155 | 0.070 |
Why?
| | Collagen Type II | 1 | 2007 | 54 | 0.060 |
Why?
| | Cell Movement | 1 | 2012 | 973 | 0.060 |
Why?
| | Curettage | 1 | 2006 | 8 | 0.060 |
Why?
| | Biomechanical Phenomena | 3 | 2018 | 870 | 0.060 |
Why?
| | Therapies, Investigational | 1 | 2006 | 18 | 0.060 |
Why?
| | Metacarpophalangeal Joint | 1 | 2006 | 22 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2006 | 991 | 0.060 |
Why?
| | Joint Instability | 1 | 2008 | 170 | 0.060 |
Why?
| | Glucosamine | 1 | 2006 | 14 | 0.060 |
Why?
| | Bone Transplantation | 1 | 2006 | 86 | 0.060 |
Why?
| | Osteoarthritis, Knee | 2 | 2019 | 274 | 0.060 |
Why?
| | Transforming Growth Factor beta3 | 1 | 2025 | 11 | 0.060 |
Why?
| | Perfusion | 1 | 2006 | 244 | 0.060 |
Why?
| | Prospective Studies | 2 | 2016 | 7900 | 0.060 |
Why?
| | Adrenal Cortex Hormones | 1 | 2008 | 500 | 0.050 |
Why?
| | Polydioxanone | 1 | 2004 | 4 | 0.050 |
Why?
| | Anilides | 1 | 2025 | 82 | 0.050 |
Why?
| | Phthalic Acids | 1 | 2025 | 51 | 0.050 |
Why?
| | Osteochondritis Dissecans | 1 | 2004 | 11 | 0.050 |
Why?
| | Rest | 1 | 2005 | 128 | 0.050 |
Why?
| | Bone Nails | 1 | 2004 | 63 | 0.050 |
Why?
| | Ligands | 1 | 2006 | 674 | 0.050 |
Why?
| | Lubrication | 1 | 2023 | 9 | 0.050 |
Why?
| | Compressive Strength | 2 | 2019 | 75 | 0.050 |
Why?
| | Ilium | 2 | 2013 | 30 | 0.050 |
Why?
| | Sternum | 2 | 2013 | 28 | 0.050 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2003 | 142 | 0.050 |
Why?
| | Surface Properties | 1 | 2023 | 411 | 0.050 |
Why?
| | South America | 1 | 2022 | 56 | 0.050 |
Why?
| | Biological Therapy | 1 | 2022 | 27 | 0.050 |
Why?
| | Umbilicus | 1 | 2001 | 19 | 0.040 |
Why?
| | Vitamin D | 1 | 2005 | 402 | 0.040 |
Why?
| | Cathelicidins | 1 | 2021 | 41 | 0.040 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2021 | 81 | 0.040 |
Why?
| | Transforming Growth Factor beta | 1 | 2003 | 481 | 0.040 |
Why?
| | Phenylbutazone | 1 | 2000 | 4 | 0.040 |
Why?
| | Granulation Tissue | 1 | 2000 | 7 | 0.040 |
Why?
| | Hernia, Diaphragmatic, Traumatic | 1 | 1999 | 1 | 0.040 |
Why?
| | Pain Measurement | 1 | 2002 | 550 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 1993 | 2636 | 0.040 |
Why?
| | Extracellular Matrix Proteins | 1 | 2001 | 157 | 0.040 |
Why?
| | Seasons | 1 | 2022 | 547 | 0.040 |
Why?
| | Preoperative Care | 1 | 2002 | 376 | 0.040 |
Why?
| | Phenazines | 1 | 2019 | 12 | 0.040 |
Why?
| | Gene Transfer Techniques | 1 | 2001 | 183 | 0.040 |
Why?
| | Staphylococcal Infections | 1 | 2024 | 390 | 0.040 |
Why?
| | Cancellous Bone | 1 | 2019 | 26 | 0.040 |
Why?
| | Urinary Bladder | 1 | 2001 | 191 | 0.040 |
Why?
| | Coloring Agents | 1 | 2019 | 93 | 0.040 |
Why?
| | Fantasy | 1 | 2018 | 2 | 0.040 |
Why?
| | Calcification, Physiologic | 1 | 2019 | 37 | 0.040 |
Why?
| | Animals, Domestic | 1 | 1998 | 18 | 0.040 |
Why?
| | Animals, Newborn | 1 | 2001 | 894 | 0.040 |
Why?
| | Collagen | 2 | 2017 | 467 | 0.040 |
Why?
| | Respiration Disorders | 1 | 1999 | 78 | 0.040 |
Why?
| | Veterinary Medicine | 1 | 2018 | 9 | 0.040 |
Why?
| | Congresses as Topic | 1 | 2020 | 228 | 0.040 |
Why?
| | Pain | 2 | 2017 | 776 | 0.040 |
Why?
| | Tumor Virus Infections | 1 | 1998 | 50 | 0.040 |
Why?
| | Societies, Scientific | 1 | 2018 | 51 | 0.040 |
Why?
| | Shoulder Injuries | 1 | 1998 | 59 | 0.040 |
Why?
| | Sepharose | 1 | 2018 | 36 | 0.040 |
Why?
| | Drug Approval | 1 | 2019 | 88 | 0.040 |
Why?
| | Biofilms | 1 | 2021 | 278 | 0.030 |
Why?
| | Joint Dislocations | 1 | 1998 | 56 | 0.030 |
Why?
| | Movement Disorders | 1 | 2018 | 69 | 0.030 |
Why?
| | Serum | 1 | 2018 | 58 | 0.030 |
Why?
| | Papillomaviridae | 1 | 1998 | 121 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 5761 | 0.030 |
Why?
| | Drug Discovery | 1 | 2019 | 155 | 0.030 |
Why?
| | Rupture | 1 | 2017 | 86 | 0.030 |
Why?
| | Xeroradiography | 1 | 1997 | 1 | 0.030 |
Why?
| | Tarsus, Animal | 1 | 1997 | 2 | 0.030 |
Why?
| | Radiotherapy Dosage | 1 | 2017 | 283 | 0.030 |
Why?
| | Radionuclide Imaging | 1 | 1997 | 113 | 0.030 |
Why?
| | Transcriptome | 1 | 2024 | 1047 | 0.030 |
Why?
| | Animals, Laboratory | 1 | 2017 | 21 | 0.030 |
Why?
| | Terminology as Topic | 1 | 2019 | 254 | 0.030 |
Why?
| | Musculoskeletal System | 1 | 2017 | 48 | 0.030 |
Why?
| | Fecal Impaction | 1 | 1996 | 5 | 0.030 |
Why?
| | Colic | 1 | 1996 | 8 | 0.030 |
Why?
| | Cellular Senescence | 1 | 2018 | 229 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 2017 | 1054 | 0.030 |
Why?
| | Neutrophils | 1 | 2021 | 1144 | 0.030 |
Why?
| | Erythrocyte Count | 1 | 2014 | 21 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2019 | 1065 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2017 | 1057 | 0.030 |
Why?
| | Papillomavirus Infections | 1 | 1998 | 354 | 0.030 |
Why?
| | Cell Count | 1 | 2014 | 324 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 1047 | 0.030 |
Why?
| | Lymph Nodes | 1 | 1996 | 502 | 0.020 |
Why?
| | Reference Values | 1 | 2014 | 806 | 0.020 |
Why?
| | Ligation | 1 | 2012 | 92 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2017 | 1984 | 0.020 |
Why?
| | Apoptosis | 1 | 2020 | 2446 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2018 | 3614 | 0.020 |
Why?
| | Risk Factors | 1 | 2005 | 10623 | 0.020 |
Why?
| | Clavulanic Acids | 1 | 2010 | 1 | 0.020 |
Why?
| | Ticarcillin | 1 | 2010 | 1 | 0.020 |
Why?
| | Therapeutic Irrigation | 1 | 2010 | 70 | 0.020 |
Why?
| | Rats | 1 | 2018 | 5609 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 6004 | 0.020 |
Why?
| | Fractures, Comminuted | 1 | 2008 | 21 | 0.020 |
Why?
| | Carpal Bones | 1 | 2008 | 17 | 0.020 |
Why?
| | Proteins | 1 | 2014 | 1023 | 0.020 |
Why?
| | Stress, Psychological | 1 | 2017 | 1147 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2010 | 483 | 0.020 |
Why?
| | Joints | 1 | 2007 | 108 | 0.020 |
Why?
| | Gene Silencing | 1 | 2007 | 202 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2007 | 382 | 0.010 |
Why?
| | Bone Matrix | 1 | 2005 | 8 | 0.010 |
Why?
| | RNA Interference | 1 | 2007 | 482 | 0.010 |
Why?
| | Debridement | 1 | 2004 | 88 | 0.010 |
Why?
| | Base Sequence | 1 | 2007 | 2186 | 0.010 |
Why?
| | Interleukin-1 | 1 | 2007 | 962 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2007 | 2914 | 0.010 |
Why?
| | Surgical Flaps | 1 | 2004 | 144 | 0.010 |
Why?
| | Urinary Bladder Fistula | 1 | 2001 | 11 | 0.010 |
Why?
| | Hernia, Umbilical | 1 | 2001 | 20 | 0.010 |
Why?
| | Prognosis | 1 | 2010 | 4211 | 0.010 |
Why?
| | Aggrecans | 1 | 2001 | 15 | 0.010 |
Why?
| | Lectins, C-Type | 1 | 2001 | 63 | 0.010 |
Why?
| | Blotting, Northern | 1 | 2001 | 202 | 0.010 |
Why?
| | Graft Survival | 1 | 2003 | 510 | 0.010 |
Why?
| | Immunoenzyme Techniques | 1 | 2001 | 200 | 0.010 |
Why?
| | Models, Biological | 1 | 2007 | 1833 | 0.010 |
Why?
| | Knee Joint | 1 | 2003 | 414 | 0.010 |
Why?
| | Reindeer | 1 | 1998 | 4 | 0.010 |
Why?
| | Goats | 1 | 1998 | 25 | 0.010 |
Why?
| | Respiration | 1 | 1999 | 209 | 0.010 |
Why?
| | Deer | 1 | 1998 | 34 | 0.010 |
Why?
| | Transfection | 1 | 2001 | 952 | 0.010 |
Why?
| | Shoulder Joint | 1 | 1998 | 176 | 0.010 |
Why?
| | DNA | 1 | 2003 | 1427 | 0.010 |
Why?
| | Swine | 1 | 1998 | 843 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 1999 | 1502 | 0.010 |
Why?
| | Respiration, Artificial | 1 | 1999 | 706 | 0.010 |
Why?
| | Adult | 1 | 2010 | 40128 | 0.000 |
Why?
|
|
Goodrich's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|